CN1823761A - 一种用于治疗肝病的益肝灵分散片及其制备方法 - Google Patents
一种用于治疗肝病的益肝灵分散片及其制备方法 Download PDFInfo
- Publication number
- CN1823761A CN1823761A CN 200510135679 CN200510135679A CN1823761A CN 1823761 A CN1823761 A CN 1823761A CN 200510135679 CN200510135679 CN 200510135679 CN 200510135679 A CN200510135679 A CN 200510135679A CN 1823761 A CN1823761 A CN 1823761A
- Authority
- CN
- China
- Prior art keywords
- silymarin
- parts
- content
- ling
- gan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 15
- 208000019423 liver disease Diseases 0.000 title claims description 12
- 239000006185 dispersion Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims description 44
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims description 44
- 229960004245 silymarin Drugs 0.000 claims description 33
- 235000017700 silymarin Nutrition 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000007919 dispersible tablet Substances 0.000 claims description 22
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 18
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 18
- 239000008187 granular material Substances 0.000 claims description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 14
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 12
- SEBFKMXJBCUCAI-DBMPWETRSA-N silybin Chemical compound C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-DBMPWETRSA-N 0.000 claims description 12
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 11
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 11
- 235000014899 silybin Nutrition 0.000 claims description 11
- 229950000628 silibinin Drugs 0.000 claims description 10
- 239000000080 wetting agent Substances 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000005229 liver cell Anatomy 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 239000000654 additive Substances 0.000 abstract 1
- 230000003908 liver function Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 9
- 239000002994 raw material Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940043175 silybin Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
物料名称 | 处方1 | 物料名称 | 处方2 | 物料名称 | 处方3 |
水飞蓟素CMS磷酸氢钙80%乙醇颗粒含水量崩解(分)硬度(KG)外观 | 1163Q.S约4%42.8部分易碎 | 水飞蓟素CMS磷酸氢钙60%乙醇颗粒含水量崩解(分)硬度(KG)外观 | 1154Q.S约4%53.6良好 | 水飞蓟素CMS磷酸氢钙40%乙醇颗粒含水量崩解(分)硬度(KG)外观 | 1145Q.S约4%3.84.5部分有麻点 |
物料名称 | 处方4 | 物料名称 | 处方5 | 物料名称 | 处方6 |
水飞蓟素L-HPCMCC磷酸氢钙60%乙醇颗粒含水量崩解(分)硬度(KG) | 11324Q.S约4%1.04 | 水飞蓟素L-HPCMCC60%乙醇颗粒含水量崩解(分)硬度(KG) | 1172Q.S约4%2.04.3 | 水飞蓟素L-HPC磷酸氢钙60%乙醇颗粒含水量崩解(分)硬度(KG) | 1172Q.S约4%1.53.5 |
物料名称 | 处方7 | 物料名称 | 处方8 |
水飞蓟素L-HPC磷酸氢钙60%乙醇颗粒含水量崩解(分)硬度(KG) | 1136Q.S约4%1.03.8 | 水飞蓟素L-HPCMCC60%乙醇颗粒含水量崩解(分)硬度(KG) | 1136Q.S约4%2.04.4 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510135679A CN100586432C (zh) | 2005-12-31 | 2005-12-31 | 一种用于治疗肝病的益肝灵分散片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510135679A CN100586432C (zh) | 2005-12-31 | 2005-12-31 | 一种用于治疗肝病的益肝灵分散片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1823761A true CN1823761A (zh) | 2006-08-30 |
CN100586432C CN100586432C (zh) | 2010-02-03 |
Family
ID=36934704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200510135679A Active CN100586432C (zh) | 2005-12-31 | 2005-12-31 | 一种用于治疗肝病的益肝灵分散片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100586432C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101856396B (zh) * | 2009-04-07 | 2012-07-25 | 北京天科仁祥医药科技有限公司 | 一种治疗乙型肝炎的分散片及其制备方法 |
CN106511757A (zh) * | 2016-11-10 | 2017-03-22 | 苏州慧宁堂生物科技有限公司 | 一种水飞蓟素虫草含片及制备方法 |
-
2005
- 2005-12-31 CN CN200510135679A patent/CN100586432C/zh active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101856396B (zh) * | 2009-04-07 | 2012-07-25 | 北京天科仁祥医药科技有限公司 | 一种治疗乙型肝炎的分散片及其制备方法 |
CN106511757A (zh) * | 2016-11-10 | 2017-03-22 | 苏州慧宁堂生物科技有限公司 | 一种水飞蓟素虫草含片及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100586432C (zh) | 2010-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1823761A (zh) | 一种用于治疗肝病的益肝灵分散片及其制备方法 | |
CN1297304C (zh) | 陈香露白露干混悬剂及其制备方法 | |
CN101028329A (zh) | 一种叶下珠分散片制剂的制备方法及其应用 | |
CN106420637A (zh) | 一种富马酸酮替芬片及其制备方法 | |
CN108186636A (zh) | 一种治疗糖尿病前期的药物组合物 | |
CN109513008B (zh) | 一种治疗特发性间质性肺炎的药物组合物及其制备方法 | |
CN1481805A (zh) | 一种治疗肝炎的药物及其制备方法 | |
CN1698701A (zh) | 一种痛风舒片及其制备方法 | |
CN1245163C (zh) | 葛根素分散片组合物及其制备方法 | |
CN1704062A (zh) | 齐墩果酸缓释片及其制备方法 | |
CN1857289A (zh) | 一种复方甘草酸及其盐的分散片剂及其制备方法 | |
CN104367563A (zh) | 一种含有灰树花的片剂及其制备方法 | |
CN1883644A (zh) | 一种治疗妇科疾病的中药片剂及其制备工艺 | |
CN1695721A (zh) | 治疗急、慢性肝炎及肝硬化的中药分散片及其制备方法 | |
CN116459347B (zh) | 一种基于甘露醇和微晶纤维素的复合辅料及其制备方法 | |
CN1416892A (zh) | 生物菌粉复方咳喘药片 | |
CN101564457A (zh) | 三白草木脂素分散片 | |
CN1990012A (zh) | 三黄分散片 | |
CN1626210A (zh) | 治疗泌尿系统等疾病的三金药物制剂及其制备方法 | |
CN1927372A (zh) | 抗病毒分散片及其制备方法 | |
CN1337245A (zh) | 一种治疗感冒的药物 | |
Guangci et al. | Overview of Pharmaceutical Research on the Poria with Hostwood of Traditional Chinese Medicine. | |
CN1626089A (zh) | 伐昔洛韦口腔崩解片及制备方法 | |
CN1186668A (zh) | 盐酸青藤碱制剂及其制备工艺 | |
CN1593398A (zh) | 黄豆苷元分散片组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Hu Kefei Document name: the First Notification of an Office Action |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Effective date: 20110830 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20110830 Address after: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 4002 Patentee after: Beijing Increase Pharmaceutical Technology Co., Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: Beijing Yinkeruisi Biological Products Research Institute |
|
ASS | Succession or assignment of patent right |
Owner name: ZHUHAI BAODE RUNSHENG HEALTH TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: BEIJING INCREASE PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20150320 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100088 XICHENG, BEIJING TO: 519040 ZHUHAI, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150320 Address after: 519040 Guangdong city of Zhuhai province Jinwan District Sanzao Town Airport Road No. 288 building four floor F area B Patentee after: Zhuhai Bao Derun Health Technology Co., Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 4002 Patentee before: Beijing Increase Pharmaceutical Technology Co., Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20161223 Address after: Beijing city Changping District town Beiqijia Hongfu building room 1009 Patentee after: BEIJING INCREASE PHARMACEUTICAL INSTITUTE CO., LTD. Address before: 519040 Guangdong city of Zhuhai province Jinwan District Sanzao Town Airport Road No. 288 building four floor F area B Patentee before: Zhuhai Bao Derun Health Technology Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170628 Address after: Room 20, 408, creative Valley, 1889 Huandao East Road, Hengqin New District, Xiangzhou, Guangdong, Zhuhai Patentee after: Ying Kerui (Hengqin) Pharmaceutical Research Institute Co Ltd Address before: Beijing city Changping District town Beiqijia Hongfu building room 1009 Patentee before: BEIJING INCREASE PHARMACEUTICAL INSTITUTE CO., LTD. |
|
TR01 | Transfer of patent right |